The oncological and reproductive outcomes of fertility-preserving treatments for stage 1 grade 1 endometrial carcinoma: a systematic review and meta-analysis.
| Autor: | Ogunbiyi MO; University College London Hospitals NHS Foundation Trust, London, UK., Oxley S; University College London Hospitals NHS Foundation Trust, London, UK., Graham R; University College London Hospitals NHS Foundation Trust, London, UK., Olaitan A; University College London Hospitals NHS Foundation Trust, London, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology [J Obstet Gynaecol] 2024 Dec; Vol. 44 (1), pp. 2294329. Date of Electronic Publication: 2023 Dec 21. |
| DOI: | 10.1080/01443615.2023.2294329 |
| Abstrakt: | Introduction: The number of patients desiring fertility-preserving treatment for endometrial cancer rather than standard surgical management continues to increase. Objective: We aimed to evaluate the efficacies of fertility-preserving treatments on the live birth rate, remission and relapse rates for women with stage 1a grade 1 endometrial carcinoma to support patient counselling. Methods: We performed a meta-analysis for our primary outcomes of overall remission and relapse rate, and for secondary analysis, we divided papers into treatment type: systemic progestins, intrauterine progestins or hysteroscopic resection and adjuvant hormonal treatment. Results: Thirty-five observational studies met inclusion criteria, with a total of 624 patients. Overall, conservative treatment of endometrial cancer showed a remission rate of 77% (95% CI: 70-84%), a relapse rate of 20% (95% CI: 13-27%) and a live birth rate of 20% (95% CI: 15-25%) with more favourable outcomes for the hysteroscopic resection group. Conclusions: Hysteroscopic resection and adjuvant hormonal treatment had the most favourable fertility and oncological outcomes. Further high-quality prospective multi-centre trials are warranted to determine the optimal treatment regimen and dosage and risk stratification for these patients. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|